Exploratory Efficacy Results from the TANDEM Trial: Safety, Tolerability, and Efficacy of Ubrogepant for the Acute Treatment of Migraine in Participants Taking Atogepant for the Preventive Treatment of Episodic Migraine (P8-12.002)
Evaluate efficacy of ubrogepant 100mg PRN for the acute treatment of migraine in participants taking atogepant 60mg QD for the preventive treatment of EM.
Authors
- Casey Schlacher
- Janette Contreras‐De Lama (ORCID: https://orcid.org/0009-0005-9032-7676)
- Andrew Blumenfeld (ORCID: https://orcid.org/0000-0003-0851-4914)
- Molly Yizeng He
- Jonathan Smith (ORCID: https://orcid.org/0000-0001-8300-4426)
- Linda Lindsey Davis
Institutions
- AbbVie (United States) (US)
- Pain and Headache Center (US)
- AbbVie (Japan)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000210691
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00